Elanco Animal Health Incorporated Common Stock (ELAN) Stock Price

ELANStock

$23.55+14.77%52W

Market Cap$11.77B

P/E38.83x

PEG Ratio4.04

Div yield—

Beta1.74

ELAN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-12.23%

Price vs S&P 500 (4W)6.32%

PEG Ratio4.04

VGM Score59.80

P/E Ratio (Annual)38.83x

P/CF (Annual)21.01x

Book Value / Share (Quarterly)$13.19

P/TBV (Annual)3.58x

Revenue Growth (3Y)2.25%

Cash Flow / Share (Quarterly)$0.76

Price vs S&P 500 (YTD)-7.86%

Gross Margin (TTM)55.36%

Net Profit Margin (TTM)-3.96%

EPS (TTM)$-0.42

10-Day Avg Trading Volume4.79M

EPS Excl Extra (TTM)$-0.42

Revenue Growth (5Y)7.59%

EPS (Annual)$-0.47

ROI (Annual)-2.20%

Gross Margin (Annual)54.99%

Net Profit Margin (5Y Avg)-7.42%

Cash / Share (Quarterly)$1.06

P/E Basic Excl Extra (TTM)364.59x

Revenue Growth QoQ (YoY)10.23%

EPS Growth (5Y)29.95%

P/E Normalized (Annual)38.83x

ROA (Last FY)-1.74%

Revenue Growth TTM (YoY)11.95%

EBITD / Share (TTM)$0.78

ROE (5Y Avg)-5.05%

Operating Margin (TTM)-3.33%

Cash Flow / Share (Annual)$0.57

P/B Ratio1.79x

P/B Ratio (Quarterly)1.87x

Net Income / Employee (Annual)$-24,700

EV / Revenue (TTM)3.02x

Net Interest Coverage (TTM)3.08x

ROA (TTM)-1.48%

EPS Growth QoQ (YoY)385.00%

EV / EBITDA (TTM)38.96x

EPS Incl Extra (Annual)$-0.47

Current Ratio (Annual)2.17x

Quick Ratio (Quarterly)0.91x

3-Month Avg Trading Volume5.81M

52-Week Price Return14.77%

EV / Free Cash Flow (Annual)53.36x

P/E Incl Extra (TTM)364.59x

Revenue / Employee (TTM)$534,000

Tangible BV / Share (Quarterly)$6.77

P/S Ratio (Annual)2.50x

Asset Turnover (Annual)0.35x

52-Week High$27.98

Operating Margin (5Y Avg)-1.82%

EPS Excl Extra (Annual)$-0.47

CapEx CAGR (5Y)-2.35%

Tangible BV CAGR (5Y)8.49%

26-Week Price Return-2.32%

Quick Ratio (Annual)0.93x

13-Week Price Return-8.83%

Total Debt / Equity (Annual)0.61x

Current Ratio (Quarterly)2.05x

Enterprise Value$15.15B

Revenue / Share Growth (5Y)5.09%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)-6.01%

Revenue / Employee (Annual)$501,600

Inventory Turnover (Annual)1.28x

Pretax Margin (Annual)-4.75%

Cash / Share (Annual)$1.10

3-Month Return Std Dev37.10%

Gross Margin (5Y Avg)55.61%

Net Income / Employee (TTM)$-21,200

EBITDA CAGR (5Y)28.45%

EBITDA Interim CAGR (5Y)12.82%

ROE (Last FY)-3.54%

Net Interest Coverage (Annual)3.08x

EPS Basic Excl Extra (Annual)$-0.47

P/FCF (TTM)28.22x

Receivables Turnover (TTM)4.86x

EV / Free Cash Flow (TTM)39.98x

Total Debt / Equity (Quarterly)0.59x

EPS Incl Extra (TTM)$-0.42

Receivables Turnover (Annual)5.62x

ROI (TTM)-1.88%

P/S Ratio (TTM)2.34x

Pretax Margin (5Y Avg)-6.89%

Revenue / Share (Annual)$9.50

Tangible BV / Share (Annual)$6.32

Forward P/E20.71x

Free OCF CAGR (5Y)70.08%

Price vs S&P 500 (52W)-0.77%

P/E Ratio (TTM)364.59x

EPS Growth TTM (YoY)-82.48%

Year-to-Date Return4.07%

5-Day Price Return4.39%

EPS Normalized (Annual)$-0.47

ROA (5Y Avg)-2.21%

Net Profit Margin (Annual)-4.92%

Month-to-Date Return5.18%

Cash Flow / Share (TTM)$-0.92

EBITD / Share (Annual)$0.68

Operating Margin (Annual)-4.35%

LT Debt / Equity (Annual)0.57x

P/CF (TTM)19.07x

ROI (5Y Avg)-2.66%

P/E Excl Extra (TTM)364.59x

LT Debt / Equity (Quarterly)0.58x

EPS Basic Excl Extra (TTM)$-0.42

P/TBV (Quarterly)3.63x

P/B Ratio (Annual)1.72x

Inventory Turnover (TTM)1.30x

Pretax Margin (TTM)-3.31%

Book Value / Share (Annual)$13.17

Price vs S&P 500 (13W)-11.51%

Net Margin Growth (5Y)28.06%

Beta1.74x

P/FCF (Annual)41.43x

Revenue / Share (TTM)$9.92

ROE (TTM)-3.02%

52-Week Low$19.40

vGradeD

gGradeB

mGradeB

vgmGradeC

ELAN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.27	$0.34	+26.46%(+$0.07)
Q1 2026	May 6, 2026	$0.34	$0.40	+16.60%(+$0.06)
Q4 2025	Feb 24, 2026	$0.12	$0.13	+11.21%(+$0.01)
Q3 2025	Nov 5, 2025	$0.13	$0.19	+43.85%(+$0.06)
Q2 2025	Aug 7, 2025	$0.20	$0.26	+29.52%(+$0.06)

ELAN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.32

4.35

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78
MIRMMirum Pharmaceuticals, Inc. Common Stock	F	B	C	8.4x	44.0%	81.7%	—	$80.14

About Elanco Animal Health Incorporated Common Stock

Elanco Animal Health is a global pharmaceutical company serving the companion and food animal markets with products sold in over 90 countries. The company's portfolio spans cattle, sheep, goats, swine, and companion animals, built through a combination of internal development and strategic acquisitions that have strengthened its market position.

ELAN Next Earnings Report

Report dateNov 6, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate$0.21

Revenue estimate$1.21B

Also reporting on Nov 6, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

ELAN Insider Transactions

BuyAug 20, 2026
KURZIUS LAWRENCE ERIK
Director
Shares: 40,000Value: $935,920
BuyAug 18, 2026
O'NEILL SHIV
Officer
Shares: 3,998Value: $94,273
BuyAug 12, 2026
HARRINGTON MICHAEL J
Director
Shares: 5,000Value: $109,100
BuyAug 7, 2026
HERENDEEN PAUL S
Director
Shares: 10,000Value: $236,850
BuyAug 7, 2026
VANHIMBERGEN ROBERT M
Chief Financial Officer
Shares: 4,200Value: $96,926

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

EXELExelixis IncBiological Products
HALOHalozyme Therapeutics, Inc.Biological Products
NBIXNeurocrine Biosciences IncBiological Products
RPMRPM International, Inc.Paints & Coatings
TECHBio-Techne Corp.Biological Products
ALBAlbemarle CorporationPlastics & Resins
RGENRepligen CorpBiological Products
CLXClorox CompanyCleaning & Polishing Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$19.40

High$27.98